Rhumbline Advisers Has $904,000 Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Rhumbline Advisers lessened its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 2.8% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 56,023 shares of the company’s stock after selling 1,634 shares during the period. Rhumbline Advisers owned approximately 0.09% of Spyre Therapeutics worth $904,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Spyre Therapeutics by 4.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,741 shares of the company’s stock valued at $527,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Spyre Therapeutics in the fourth quarter valued at approximately $29,000. MetLife Investment Management LLC grew its stake in Spyre Therapeutics by 6.2% in the fourth quarter. MetLife Investment Management LLC now owns 21,382 shares of the company’s stock valued at $498,000 after acquiring an additional 1,250 shares during the period. Huntington National Bank acquired a new stake in Spyre Therapeutics in the fourth quarter valued at approximately $34,000. Finally, Arizona State Retirement System grew its stake in Spyre Therapeutics by 38.4% in the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock valued at $235,000 after acquiring an additional 2,805 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wedbush reissued an “outperform” rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a research note on Monday, May 5th. Leerink Partnrs raised Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 8th. Leerink Partners initiated coverage on Spyre Therapeutics in a research report on Tuesday, April 8th. They set an “outperform” rating and a $45.00 target price on the stock. Finally, Wolfe Research initiated coverage on Spyre Therapeutics in a research report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Spyre Therapeutics presently has an average rating of “Buy” and an average target price of $53.40.

Spyre Therapeutics Stock Down 0.5%

Shares of NASDAQ:SYRE opened at $15.01 on Friday. The stock has a market cap of $904.80 million, a price-to-earnings ratio of -3.98 and a beta of 2.72. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $40.26. The business’s 50 day moving average is $14.98 and its 200 day moving average is $18.79.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. As a group, equities research analysts expect that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).